

ONLINE FIRST PUBLICATION

Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs number provided. Mandatory typesetting and proofreading will commence with regular print and online publication of the online first papers of the *SMJ*.

***Malassezia*: a case of coexisting pityriasis versicolor and
Malassezia folliculitis**

Ellie Choi¹, MBBS, MMed, Chris Lixian Tan¹, MBBS, MMed, Derrick Aw², MBBS, MMed

¹Division of Dermatology, National University Hospital, ²Department of General Medicine, Sengkang General Hospital, Singapore

Correspondence: Dr Ellie Choi, Division of Dermatology, National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074. ellie_choi@nuhs.edu.sg

Singapore Med J 2018, 1–3
<https://doi.org/10.11622/smedj.2018079>
Published ahead of print: 21 June 2018

Online version can be found at
<http://www.smj.org.sg/online-first>

Dear Sir,

In the human fungal biodata, *Malassezia* is the dominant species. It is a skin commensal that has been implicated in diseases such as pityriasis versicolor (PV), *Malassezia* folliculitis (MF), seborrhoeic dermatitis, atopic dermatitis and psoriasis.⁽¹⁾ Environmental factors such as increased temperature, sweating, seborrhoea,⁽²⁾ and immunosuppressive conditions such as human immunodeficiency virus (HIV) infections, diabetes mellitus and corticosteroid use predispose to the development of PV and MF.⁽³⁾

A 24-year-old Chinese man was referred to the dermatology clinic for an asymptomatic rash on his back, arms, thighs and buttocks of two months' duration. The patient had a past medical history of Evan's syndrome (autoimmune thrombocytopenia and haemolytic anaemia), for which he was on long-term azathioprine and prednisolone for immunosuppression. He was otherwise well and had no constitutional symptoms. On examination of the affected areas, there was a monomorphic erythematous pustular eruption with multiple annular scaly hypopigmented macules and patches within (Fig. 1). A fungal scrape from lesional areas was positive for hyphae and spores.



Fig. 1 Clinical photograph of the left arm shows erythematous monomorphic pustules interspersed with hypopigmented scaly macules and plaques.

The diagnosis of concurrent PV and MF was made. Lifestyle modification with avoidance of humid conditions was advised. He was treated with topical miconazole cream and a three-week course of oral ketoconazole 200 mg BD. The rash improved marginally and he

was given a further two-week course of oral ketoconazole. At that time, the haematologist also added cyclophosphamide to his immunosuppressive regime. After a total of five weeks of oral antifungals, his rash still failed to resolve. He was then prescribed itraconazole 200 mg OM for one week, followed by 100 mg OM for three weeks, which resulted in successful eradication of disease.

The various manifestations of *Malassezia* infections differ based on pathophysiology. For PV, lipase produced by *Malassezia* metabolises various fatty acids, producing metabolites (such as azelaic acid) that block the passage of tyrosine to melanin, resulting in hypopigmented macules.⁽²⁾ The predominant species is *M. globosa*.⁽⁴⁾ Microscopy shows the typical ‘spaghetti and meatballs’ appearance of both hyphae and spores, and this dimorphic appearance is unique to PV.⁽⁵⁾ There is an absence of an inflammatory infiltrate in histopathology.⁽⁶⁾ Conversely, MF is characterised by an inflammatory response to invasion of hair follicles and hydrolysis of triglycerides with yeast, resulting in erythematous papules or pustules.⁽¹⁾ The predominant species involved are *M. restricta*, *M. globosa* and *M. sympodialis*.⁽¹⁾ Microscopically, only budding yeast cells are seen.⁽⁷⁾

The azole drugs, such as ketoconazole, itraconazole and voriconazole, have high *in vitro* antifungal efficacy in *Malassezia* species and are good options for systemic management of *Malassezia* infections,⁽⁸⁾ although a prolonged course may be necessary for clinical resolution, as illustrated in this case.

The presentation of both PV and MF in the same patient and at the same location highlights that two different pathological processes can occur simultaneously. The use of augmented immunosuppressive therapy may have predisposed the patient to dual manifestations of *Malassezia* infections.

Yours sincerely,

Ellie Choi¹, Chris Lixian Tan¹, Derrick Aw²

REFERENCES

1. Harada K, Saito M, Sugita T, Tsuboi R. Malassezia species and their associated skin diseases. *J Dermatol* 2015; 42:250-7.
2. Mendez-Tovar LJ. Pathogenesis of dermatophytosis and tinea versicolor. *Clin Dermatol* 2010; 28:185-9.
3. Tragiannidis A, Bisping G, Koehler G, Groll AH. Minireview: Malassezia infections in immunocompromised patients. *Mycoses* 2010; 53:187-95.
4. Crespo Erchiga V, Ojeda Martos A, Vera Casaño A, Crespo Erchiga A, Sanchez Fajardo F. Malassezia globosa as the causative agent of pityriasis versicolor. *Br J Dermatol* 2000; 143:799-803.
5. Gupta AK, Batra R, Bluhm R, Boekhout T, Dawson TL Jr. Skin diseases associated with Malassezia species. *J Am Acad Dermatol* 2004; 51:785-98.
6. Wroblewski N, Bär S, Mayser P. [Missing granulocytic infiltrate in pityriasis versicolor-- indication of specific anti-inflammatory activity of the pathogen?] *Mycoses* 2005; 48 Suppl 1:66-71. German.
7. Ayers K, Sweeney SM, Wiss K. Pityrosporum folliculitis: diagnosis and management in 6 female adolescents with acne vulgaris. *Arch Pediatr Adolesc Med* 2005; 159:64-7.
8. Gupta AK, Kohli Y, Li A, Faergemann J, Summerbell RC. In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine. *Br J Dermatol* 2000; 142:758-65.